What we do

Ankrin Therapeutics is developing inhibitors against essential protein-protein interactions required for homologous recombination repair of toxic DNA lesions. Our drug discovery pipeline combines both structure-based drug design and high-throughput screening strategies.

Our goal

Ankrin Therapeutics aims to create innovation in precision oncology by exploiting inherent DNA repair dependencies. We will leverage novel, proprietary, and well-characterized protein targets to develop first-in-class drugs against homologous recombination.


Ankrin team